Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
Teclistamab Immunotherapy – Review
Biotech & Bioprocessing Teclistamab Immunotherapy – Review

The therapeutic landscape for multiple myeloma has long been defined by a relentless cycle of remission and relapse, leaving many patients with few options once primary defenses fail. Teclistamab, marketed as Tecvayli, has emerged as a transformative solution to this exhaustion, functioning as a

Researchers Decode Protein Switch for Vascular Health
Tech & Innovation Researchers Decode Protein Switch for Vascular Health

The intricate network of blood vessels that sustains human life depends entirely on the structural integrity of the endothelium, a microscopic cellular barrier that regulates the flow of life-sustaining nutrients while keeping harmful toxins at bay. When this delicate system fails, the consequences

Integrating Genomic Tools Into Rare Disease Diagnostics
Tech & Innovation Integrating Genomic Tools Into Rare Disease Diagnostics

The diagnostic odyssey for patients with rare diseases has historically been a grueling marathon characterized by years of uncertainty, misdiagnosis, and invasive testing that often yielded no actionable results for families in distress. In the current medical landscape of 2026, the shift from

Is LabVantage CORTEX the Future of Autonomous Laboratories?
Tech & Innovation Is LabVantage CORTEX the Future of Autonomous Laboratories?

Ivan Kairatov is a distinguished expert in biopharmaceutical informatics with a deep-seated passion for merging high-tech innovation with practical research and development. With years of experience navigating the complexities of laboratory environments, he has become a leading voice in the

How Do Cholesterol Levels and Changes Affect Mortality Risk?
Research & Development How Do Cholesterol Levels and Changes Affect Mortality Risk?

The standard medical narrative has long insisted that lower cholesterol levels are synonymous with better health outcomes, yet recent large-scale data suggests a far more nuanced reality exists for the general population. A comprehensive 2025 study involving nearly half a million participants from

How Does Ketamine Reshape the Depressed Brain?
Tech & Innovation How Does Ketamine Reshape the Depressed Brain?

The historical reliance on traditional monoaminergic antidepressants has left a significant portion of the psychiatric patient population in a state of perpetual search for relief, particularly those suffering from treatment-resistant depression. While standard selective serotonin reuptake

How Is Our View of the Aging Brain Changing?
Tech & Innovation How Is Our View of the Aging Brain Changing?

The longstanding myth that the human brain inevitably deteriorates at a fixed rate after middle age is finally being dismantled by a new wave of multidimensional research. For decades, the prevailing scientific narrative suggested a linear and universal decline in cognitive function as individuals

Study Identifies New Signaling Axis in Nervous System Tumors
Research & Development Study Identifies New Signaling Axis in Nervous System Tumors

The most formidable barrier to treating aggressive brain cancer may not be the physical skull or the blood-brain barrier, but the cellular invisibility cloak that allows these tumors to ignore the body’s natural defenses. For decades, the primary strategy in oncology has been to train the immune

How Is Apple’s New Strategy Redefining Its Ecosystem?
Tech & Innovation How Is Apple’s New Strategy Redefining Its Ecosystem?

The current technological landscape is witnessing a massive transformation as Apple systematically dismantles its long-standing reliance on external partners to forge a path of total hardware and software autonomy. This strategic pivot is most visible in the recent unveiling of the M5 chip

Can J&J’s New Approval Redefine Multiple Myeloma Care?
Research & Development Can J&J’s New Approval Redefine Multiple Myeloma Care?

The sudden transformation of multiple myeloma from a terminal diagnosis to a manageable chronic condition reached a pivotal junction with the Food and Drug Administration's recent decision to grant full approval to a high-impact combination therapy. By pairing the bispecific antibody Tecvayli with

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later